Prognosis

Daiichi Sankyo Eyes Newer Cancer Drugs to Stave off Rivals

Japanese drugmaker’s new targeted cancer drug shows promise
Daiichi’s ADC win ignites competition from big pharma, China

WATCH: COO Okuzawa says Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells.WATCH: Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Natsuko Katsuki and Shery Ahn

October 11, 2024 at 12:58 AM UTC

Updated on

October 11, 2024 at 4:46 AM UTC

This article is for subscribers only.

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology, a top executive said.

The Japanese drugmaker believes its next generation of so-called antibody drug conjugate medicines that show promise in early stage human testing will help keep the company ahead of the pack, its President and Chief Operating Officer Hiroyuki Okuzawa told Bloomberg News on Friday in Tokyo.